Probiotics for Type 2 Diabetes and Prediabetes: Which Strains Actually Move the Needle on Blood Sugar and HbA1c
What peer-reviewed research reveals about specific probiotic strains and glycemic control—and which ones are backed by clinical evidence
More than 96 million American adults have prediabetes, and roughly one in three will progress to type 2 diabetes without meaningful intervention. The metabolic line between prediabetes and a full T2D diagnosis is not a wall—it's a gradual slide driven by insulin resistance, low-grade systemic inflammation, and increasingly, a disrupted gut microbiome. That last factor is where probiotics enter the conversation in a clinically meaningful way.
Research published over the past decade has established a two-directional relationship between gut microbiota composition and glycemic regulation. People with type 2 diabetes demonstrate measurably different gut microbiome profiles than metabolically healthy individuals—lower populations of beneficial Lactobacillus and Bifidobacterium species, compromised intestinal barrier integrity, and elevated levels of lipopolysaccharide (LPS)-producing bacteria that drive systemic inflammation and insulin resistance.[1]
The logical extension—that replenishing these beneficial bacteria through targeted probiotic supplementation could support glycemic control—has now been tested in dozens of randomized controlled trials and summarized in multiple systematic reviews and meta-analyses. The findings are nuanced but compelling: specific strains, at adequate doses, can produce clinically meaningful reductions in fasting blood glucose, HbA1c, and markers of insulin resistance—particularly in individuals with prediabetes and early-stage T2D.
This article focuses specifically on probiotic strains with evidence relevant to blood sugar regulation that are found in MicroBiome Restore—our 26-strain, filler-free probiotic formulation built on the same evidence-based principles guiding this research.
Key Takeaways
- Probiotics can significantly reduce fasting blood glucose and HbA1c. A systematic review and meta-analysis of randomized controlled trials concluded that probiotic supplementation significantly lowered fasting blood glucose and glycated hemoglobin in adults with type 2 diabetes.[2]
- L. acidophilus and B. lactis together improved HbA1c in a clinical trial. A double-blind, placebo-controlled RCT found that probiotic yogurt containing L. acidophilus La5 and B. lactis Bb12 significantly reduced HbA1c and fasting blood glucose in patients with T2D compared to conventional yogurt.[3]
- L. reuteri improved insulin sensitivity in a randomized controlled trial of adults with type 2 diabetes, demonstrating meaningful effects on both insulin secretion and glucose metabolism.[4]
- Multi-strain probiotic formulas outperform single-strain products in clinical studies, with greater diversity associated with broader metabolic benefits including improved fasting glucose, insulin resistance markers, and lipid profiles.[5]
- Probiotic intervention in prediabetes is time-sensitive. Emerging evidence suggests that probiotic supplementation during the prediabetic stage can slow—and in some cases, partially reverse—the metabolic trajectory toward a T2D diagnosis.[6]
- Filler-free formulation matters. Common probiotic additives like microcrystalline cellulose and titanium dioxide may interfere with gut integrity—undermining the very outcomes these interventions are designed to support.
The Gut Microbiome and Blood Sugar: A Two-Way Street
The connection between gut bacteria and metabolic health is no longer fringe science. A landmark paper by Cani et al. published in Diabetes demonstrated that high-fat diets increase intestinal permeability, allowing bacterial endotoxin (lipopolysaccharide, or LPS) to leak into the bloodstream—a state called metabolic endotoxemia—triggering systemic low-grade inflammation that directly impairs insulin signaling.[1] This was a pivotal insight: gut dysbiosis wasn't just correlated with T2D, it was mechanistically contributing to it.
Subsequent metagenome-wide research confirmed a distinct gut microbiome signature in people with type 2 diabetes. A large-scale study published in Nature found that individuals with T2D harbored reduced populations of butyrate-producing bacteria, diminished species richness, and elevated abundance of pathogenic and opportunistic organisms compared to metabolically healthy controls.[7] These microbial shifts precede—and appear to accelerate—the decline of beta-cell function and insulin sensitivity that defines T2D progression.
Why the Diabetic Gut Microbiome Looks Different
Several consistent microbiome differences emerge in research comparing T2D patients to healthy controls: significantly lower Bifidobacterium and Lactobacillus populations, reduced butyrate-producing bacteria (which maintain intestinal barrier function), and overgrowth of gram-negative bacteria that release LPS. Each of these shifts feeds back into worse glycemic control—lower Bifidobacterium means less GLP-1 stimulation, compromised barrier integrity means more LPS-driven inflammation, and LPS-driven inflammation means greater insulin resistance. Probiotics address each of these failure points simultaneously.
The gut microbiome also influences blood sugar through its effect on short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate. These metabolites—produced when beneficial gut bacteria ferment dietary fiber—stimulate the release of glucagon-like peptide 1 (GLP-1), a hormone that enhances insulin secretion and reduces postprandial glucose spikes. When beneficial bacterial populations decline, SCFA production falls, GLP-1 secretion drops, and postprandial glycemic control deteriorates.
This creates a coherent biological rationale for probiotic intervention: restoring populations of Lactobacillus and Bifidobacterium species addresses the upstream microbial shifts driving inflammation, gut permeability, and impaired GLP-1 signaling that collectively worsen glycemic outcomes. The question is not whether the mechanism is plausible—it clearly is—but which specific strains have clinical evidence supporting meaningful outcomes in humans.
How Probiotics Support Glycemic Control: The Mechanisms Behind the Research
Understanding how probiotics influence blood sugar helps clarify why certain strains are more relevant than others—and why multi-strain formulations tend to outperform single-strain products in clinical research.
Reducing Intestinal Permeability ("Leaky Gut")
Certain Lactobacillus and Bifidobacterium strains strengthen tight junction proteins between intestinal epithelial cells, reducing the translocation of bacterial endotoxins into the bloodstream. This directly attenuates the inflammatory cascade that drives insulin resistance. Lactobacillus plantarum in particular has been studied for its ability to enhance mucosal barrier integrity—a mechanism directly relevant to the metabolic endotoxemia pathway underlying T2D.[5] You can explore the research on L. plantarum gut barrier benefits in more detail on our blog.
Modulating GLP-1 and Insulin Secretion
Short-chain fatty acids produced by probiotic bacteria—particularly acetate, propionate, and butyrate—bind to G-protein coupled receptors (GPR41 and GPR43) in the intestinal lining. This stimulates the release of GLP-1 and peptide YY (PYY), both of which enhance glucose-dependent insulin secretion, slow gastric emptying, and reduce postprandial glucose excursions. Lactobacillus reuteri has been specifically studied for its ability to stimulate GLP-1 secretion, partially explaining its observed effects on insulin metabolism.[4]
Reducing Systemic Inflammation
Chronic low-grade inflammation—driven largely by LPS translocation and dysbiotic gut bacteria—activates inflammatory kinases (particularly IKKβ and JNK) that phosphorylate insulin receptor substrates (IRS-1), blocking downstream insulin signaling. Probiotics counter this through multiple pathways: reducing LPS-producing bacteria, stimulating anti-inflammatory cytokine production (IL-10), and suppressing pro-inflammatory cytokines (TNF-α, IL-6). These effects have been measured in RCTs as reductions in hs-CRP—a proxy for systemic inflammation—in T2D patients receiving probiotic supplementation.[8]
Improving Lipid Metabolism
Several probiotic strains in MicroBiome Restore—particularly L. acidophilus, L. rhamnosus, and Streptococcus thermophilus—have been associated with improvements in lipid profiles alongside glycemic outcomes. Elevated triglycerides and low HDL cholesterol are hallmark features of insulin-resistant metabolic syndrome, and their improvement through probiotic supplementation suggests systemic metabolic benefit beyond glucose control alone.[9]
Best Probiotic Strains for Blood Sugar Management
Not all probiotic strains have been studied for glycemic outcomes. Below are the strains found in MicroBiome Restore that have the most relevant clinical evidence for blood sugar support in type 2 diabetes and prediabetes. We are not citing strains that have been studied in this context but are absent from our formula.
Lactobacillus acidophilus: The Foundational Glycemic Strain
Lactobacillus acidophilus is one of the most extensively studied probiotic strains in the context of type 2 diabetes. A double-blind, placebo-controlled RCT published in Nutrition found that probiotic yogurt containing L. acidophilus La5 alongside B. lactis Bb12 produced significant reductions in HbA1c and fasting blood glucose in T2D patients over a six-week intervention period compared to conventional yogurt controls.[3] The antioxidant effects observed alongside glycemic improvement are consistent with L. acidophilus's known role in reducing oxidative stress—a key driver of pancreatic beta-cell dysfunction. Read more about the evidence behind L. acidophilus clinical benefits.
Bifidobacterium lactis: A Key Glycemic Partner
Bifidobacterium lactis has appeared repeatedly in multi-strain diabetes trials as a critical component of effective probiotic formulations. Its primary mechanism in glycemic regulation involves improving the intestinal barrier and reducing metabolic endotoxemia—the LPS-driven inflammatory state that underlies insulin resistance. When combined with L. acidophilus (as in the Ejtahed et al. trial), B. lactis contributed to meaningful reductions in both HbA1c and antioxidant markers, suggesting synergistic metabolic effects.[3]
Lactobacillus reuteri: GLP-1 Stimulation and Insulin Sensitivity
A randomized controlled trial published in Diabetes, Obesity and Metabolism by Mobini et al. (2017) investigated the specific metabolic effects of Lactobacillus reuteri DSM 17938 in adults with type 2 diabetes. The trial demonstrated that L. reuteri supplementation improved insulin sensitivity and insulin secretion, with investigators linking these effects to the strain's capacity to stimulate GLP-1 secretion through SCFA-mediated gut-endocrine signaling.[4] Explore the broader clinical evidence for L. reuteri metabolic benefits.
Lactobacillus plantarum: Gut Barrier, Inflammation, and Glucose
L. plantarum is among the most versatile and resilient probiotic species, with documented benefits for intestinal barrier integrity, inflammation reduction, and—importantly for T2D—glycemic parameters. Its production of lactic acid and SCFA metabolites supports an intestinal environment that reduces pathogenic overgrowth and LPS translocation. Multi-strain trials that include L. plantarum as a component have shown improvements in HOMA-IR (a standard measure of insulin resistance) alongside reductions in inflammatory markers.[5] Read the full breakdown on L. plantarum health benefits.
Lactobacillus rhamnosus: Insulin Resistance and Metabolic Parameters
L. rhamnosus has a well-documented track record across metabolic conditions. In the context of type 2 diabetes and prediabetes, its primary relevance lies in insulin sensitization through inflammation reduction and gut barrier support. Multi-strain trials including L. rhamnosus as a component have demonstrated improvements in fasting glucose and HOMA-IR scores, supporting its inclusion in comprehensive probiotic formulations targeting glycemic outcomes.[8]
Lactobacillus casei: Metabolic and Anti-Inflammatory Support
L. casei has been studied for its immunomodulatory properties, including its ability to reduce pro-inflammatory cytokines (TNF-α and IL-6) that are chronically elevated in T2D and directly impair insulin receptor signaling. Reductions in systemic inflammation consistently correlate with improvements in insulin sensitivity, making L. casei a mechanistically relevant addition to any multi-strain formula targeting metabolic health.
Bifidobacterium longum and Bifidobacterium bifidum: Gut Integrity and Anti-Inflammation
Bifidobacterium longum and B. bifidum support glycemic regulation through their role in maintaining intestinal barrier function and producing SCFAs that stimulate GLP-1 release. Critically, B. longum has documented anti-inflammatory effects—reducing LPS-mediated inflammatory signaling—that are directly relevant to the pathophysiology of insulin resistance. Multi-strain trials that included Bifidobacterium species demonstrated significantly improved fasting glucose and insulin resistance markers compared to placebo controls.[8] Learn more about Bifidobacterium deficiency and why restoring these populations matters for metabolic health.
Bacillus coagulans: Spore-Forming Stability with Metabolic Benefits
Bacillus coagulans is a spore-forming strain that survives the harsh gastric environment at rates higher than many conventional lactobacilli, ensuring reliable colonization of the intestinal tract. It produces L-lactic acid during fermentation and has been studied for its effects on inflammation and gut barrier function, both of which are key levers in glycemic regulation. Its spore-forming nature makes it particularly stable in multi-strain supplement formulations.
Streptococcus thermophilus: A Supporting Actor in Glycemic Trials
Streptococcus thermophilus has appeared as a component in several multi-strain fermented dairy trials that produced positive glycemic outcomes. While less studied in isolation for T2D, its role in lactic acid production and its synergistic fermentation effects with L. bulgaricus and B. lactis contribute to the overall metabolic efficacy of comprehensive probiotic formulations. Read the evidence on Streptococcus thermophilus benefits.
| Strain (in MicroBiome Restore) | Primary Mechanism for Glycemic Support | Key Evidence |
|---|---|---|
| L. acidophilus | Reduces HbA1c, FBG; antioxidant effects | Significant HbA1c reduction in RCT[3] |
| B. lactis | Gut barrier integrity; metabolic endotoxemia reduction | Improved FBG + HbA1c in double-blind RCT[3] |
| L. reuteri | GLP-1 stimulation; insulin sensitivity | Improved insulin sensitivity in T2D RCT[4] |
| L. plantarum | Gut barrier; HOMA-IR reduction; inflammation | HOMA-IR improvement in multi-strain RCTs[5] |
| L. rhamnosus | Insulin sensitization; inflammation reduction | Improved glucose and HOMA-IR in clinical trials[8] |
| L. casei | TNF-α / IL-6 reduction; insulin signaling | Anti-inflammatory effects; metabolic improvement in RCTs[8] |
| B. longum / B. bifidum | SCFA production; LPS reduction; GLP-1 stimulation | Improved FBG in multi-strain placebo-controlled trials[8] |
| Bacillus coagulans | Gut barrier; anti-inflammatory; stable colonization | Metabolic and inflammatory marker improvements |
| S. thermophilus | Lactic acid production; synbiotic fermentation support | Component of effective multi-strain glycemic trials[9] |
Every Strain Above—Plus 17 More—in One Filler-Free Formula
MicroBiome Restore delivers 26 clinically studied strains, 9 organic prebiotics, and 80+ trace minerals in a single daily capsule. No microcrystalline cellulose. No magnesium stearate. No titanium dioxide. Just 15 billion CFU of evidence-based probiotic support.
What Clinical Research Reveals About HbA1c, Fasting Glucose, and Insulin Resistance
The body of clinical evidence has grown substantially over the past decade, moving from small pilot studies to well-powered systematic reviews encompassing hundreds of randomized controlled trials and thousands of participants. Here's what the research actually shows about the magnitude and consistency of probiotic effects on key diabetes biomarkers.
The Meta-Analysis Picture
Ruan et al. published a landmark systematic review and meta-analysis in PLOS ONE that synthesized data from randomized controlled trials examining the effects of probiotics on glycemic control. The analysis found that probiotic supplementation produced statistically significant reductions in fasting blood glucose and insulin levels in diabetic populations. Notably, the effect sizes were more pronounced in trials using multi-strain formulations compared to single-strain interventions, supporting the clinical rationale for comprehensive probiotic products.[2]
A multi-strain trial by Firouzi et al. (2017), published in the European Journal of Nutrition, enrolled adults with type 2 diabetes in a 12-week, double-blind, randomized, placebo-controlled protocol. Participants receiving the multi-strain probiotic capsule demonstrated significantly reduced HbA1c and fasting blood glucose compared to controls, along with improved insulin resistance scores—findings consistent with a multi-modal mechanism of action across the gut-metabolic axis.[9]
The L. acidophilus + B. lactis Clinical Trial
The study by Ejtahed et al. is particularly instructive for understanding how specific strains translate to measurable outcomes. Over six weeks in T2D patients, probiotic yogurt containing L. acidophilus La5 and B. lactis Bb12 produced significantly greater reductions in HbA1c and fasting blood glucose than conventional yogurt without active probiotic cultures. The researchers also measured significantly improved antioxidant enzyme activity (superoxide dismutase and glutathione peroxidase)—a finding consistent with the role of oxidative stress in beta-cell dysfunction.[3] Both L. acidophilus and B. lactis are strains found in MicroBiome Restore.
Multi-Strain vs. Single-Strain: Does It Matter?
Asemi et al. investigated the metabolic effects of a multi-strain probiotic supplement in a double-blind, placebo-controlled trial published in Annals of Nutrition & Metabolism. The multi-strain formula—containing several Lactobacillus and Bifidobacterium species—significantly improved fasting glucose, serum insulin, and HOMA-IR (the standard clinical measure of insulin resistance) over the intervention period, as well as markers of oxidative stress.[8] The breadth of effect across multiple metabolic parameters supports the hypothesis that diverse strains working through complementary mechanisms produce more comprehensive benefit than any single species.
What HOMA-IR Tells Us
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is a mathematical formula using fasting glucose and fasting insulin levels to estimate how resistant a person's cells have become to insulin's signaling. A high HOMA-IR score is a strong predictor of future T2D diagnosis in prediabetic individuals. When clinical trials report probiotic supplementation reducing HOMA-IR, that's not a surrogate outcome—it's a direct measurement of improved insulin sensitivity at the cellular level, the core deficit in type 2 diabetes.
Duration Matters: Short-Term vs. Long-Term Effects
One consistent finding across meta-analyses is that probiotic interventions lasting 8 weeks or longer tend to produce greater and more consistent glycemic improvements than shorter trials. This aligns with what we understand about microbiome ecology: meaningful shifts in gut microbiota composition require time, and the downstream metabolic effects follow colonization. This has practical implications for supplementation strategy—consistent, long-term use is more relevant to glycemic outcomes than intermittent or short-course probiotic use.
Prebiotic Synergy in MicroBiome Restore
MicroBiome Restore includes 9 organic prebiotics that feed and sustain the probiotic strains throughout the gut. These include Jerusalem artichoke (a concentrated source of inulin that specifically nourishes Bifidobacterium and Lactobacillus populations) and acacia fiber, which has been shown to selectively support beneficial gut bacteria without causing the bloating associated with some other prebiotics. When probiotic strains are paired with their preferred prebiotic substrates—a combination known as a synbiotic—colonization efficiency improves, and the metabolic effects become more consistent and durable.
Probiotics for Prediabetes: Evidence for Early Intervention
Prediabetes—defined by fasting blood glucose between 100–125 mg/dL, a two-hour glucose tolerance test result of 140–199 mg/dL, or an HbA1c of 5.7–6.4%—is not a neutral holding pattern. Without intervention, approximately 15–30% of prediabetic individuals will convert to T2D within five years. The gut microbiome's role in this trajectory makes it a compelling target for early intervention.
Emerging systematic reviews and meta-analyses have begun to examine the specific effects of probiotic supplementation in prediabetic populations—distinct from studies of established T2D. A systematic review and meta-analysis of randomized controlled trials published in Probiotics and Antimicrobial Proteins found that probiotic supplementation in individuals with prediabetes produced significant improvements in fasting blood glucose and lipid parameters, with multi-strain formulas demonstrating broader metabolic effects.[6]
Prediabetes Biomarkers Probiotics May Influence
Fasting blood glucose (FBG): Reductions in FBG toward the normal range (<100 mg/dL) in prediabetic individuals are a primary outcome in intervention trials, and probiotic supplementation has shown significant effects here.[6]
HbA1c (5.7–6.4% in prediabetes): Even modest reductions in HbA1c in this range meaningfully reduce 10-year cardiovascular and diabetes risk. Clinical trials show probiotic supplementation can reduce HbA1c in at-risk populations.[3]
HOMA-IR (insulin resistance): Multi-strain probiotic supplementation has produced significant HOMA-IR reductions in metabolically compromised populations, suggesting improved insulin sensitivity before overt diabetes develops.[8]
Lipid profile: Elevated triglycerides and low HDL cholesterol are common in prediabetes. Probiotic interventions, particularly those including L. acidophilus and Streptococcus thermophilus, have shown improvements in lipid profiles alongside glycemic parameters.[9]
The mechanistic argument for probiotic intervention at the prediabetic stage is particularly strong: the gut dysbiosis driving insulin resistance, increased intestinal permeability, and systemic inflammation is present and progressive before the T2D threshold is crossed. Addressing this dysbiosis early—before the degree of beta-cell exhaustion and systemic inflammation becomes severe—offers a wider therapeutic window. As the authors of one prediabetes review noted, the absence of suitable intervention at this stage significantly increases the likelihood of T2D development.[6]
Probiotics Are Not a Substitute for Medical Care
The clinical evidence is promising, but probiotics are best understood as a complementary strategy—not a replacement for lifestyle modification, blood sugar monitoring, or prescription medications when indicated. If you have prediabetes or type 2 diabetes, discuss any supplement additions with your healthcare provider, particularly if you are managing your condition with medications that affect blood glucose.
Choosing a Probiotic for Type 2 Diabetes: What to Look For
The probiotic supplement market is enormous and largely unregulated. Most products on shelves have no clinical evidence specific to their actual formulation—they rely on strain-level research done with different doses, combinations, or manufacturing processes than what's in their capsule. Navigating this landscape requires attention to a few key criteria.
Multi-Strain Diversity Over Single-Strain Simplicity
The clinical evidence clearly favors multi-strain formulations for metabolic outcomes. The multiple pathways through which the gut microbiome influences blood sugar—gut barrier integrity, SCFA production, GLP-1 stimulation, inflammation reduction—are not all served optimally by a single species. A formula that includes Lactobacillus and Bifidobacterium species simultaneously addresses more of these mechanisms than a single-strain product. Meta-analyses consistently show stronger effect sizes with multi-strain formulations.[2]
Clean Formulation: Fillers That Undermine Gut Health
Many commercial probiotic supplements contain inactive ingredients that can directly work against gut health. Microcrystalline cellulose (MCC) is a common bulking agent with emerging concerns around intestinal mucosa irritation. Magnesium stearate is a widely-used flow agent whose effects on supplement bioavailability and gut absorption are increasingly scrutinized. Learning to identify these fillers before you buy is a skill worth developing—especially if you are supplementing for a specific therapeutic purpose like glycemic support.
MicroBiome Restore uses pullulan capsules—naturally fermented, prebiotic, and free of synthetic coatings. Pullulan capsules provide a delayed-release mechanism without the use of pharmaceutical excipients that can disrupt the very gut environment you are trying to restore. Read more about pullulan vs. HPMC capsules for gut health supplementation.
Adequate CFU and Strain Transparency
Colony-forming units (CFU) reflect viable bacterial load at the time of consumption. The clinical trials producing positive glycemic outcomes have generally used doses in the range of 1–10 billion CFU per individual strain, with multi-strain totals varying. A formula delivering 15 billion CFU across 26 strains provides therapeutic-range bacterial diversity. Critically, look for products that disclose individual strain identities rather than hiding behind proprietary blend labeling—strain identity determines whether the product has any research foundation at all.
Prebiotic Support for Sustainable Colonization
Probiotics introduced into a gut that lacks their preferred prebiotic substrates will have limited colonization efficiency. Probiotic-prebiotic combinations (synbiotics) consistently outperform standalone probiotic interventions in clinical research on metabolic outcomes. MicroBiome Restore includes 9 organic prebiotics, including Jerusalem artichoke inulin—a well-characterized substrate for Bifidobacterium and Lactobacillus growth—as well as acacia fiber, which is particularly well-tolerated by sensitive digestive systems during the adaptation phase of supplementation.
What to Look For vs. What to Avoid
Look for: Multi-strain formula with documented Lactobacillus and Bifidobacterium species; individual strain identities disclosed; included prebiotic support; filler-free formulation; pullulan or other clean capsule material; 8+ weeks of consistent use for glycemic outcomes.
Avoid: Single-strain products; formulas containing magnesium stearate, silicon dioxide, or synthetic flow agents; proprietary blends that obscure strain amounts; products without third-party testing or manufacturer transparency; hidden fillers on the label.
Built on the Science. Free From What Doesn't Belong.
MicroBiome Restore contains all of the strains discussed in this article—including L. acidophilus, B. lactis, L. reuteri, L. plantarum, L. rhamnosus, L. casei, B. longum, B. bifidum, Bacillus coagulans, and S. thermophilus—plus 16 additional evidence-backed strains, 9 organic prebiotics, and 80+ trace minerals. No titanium dioxide. No microcrystalline cellulose. No magnesium stearate.
Frequently Asked Questions
What is the best probiotic for prediabetes?
Based on clinical research, the strongest evidence favors multi-strain formulations that include both Lactobacillus and Bifidobacterium species rather than any single strain. L. acidophilus, B. lactis, L. reuteri, L. plantarum, and L. rhamnosus have the most direct clinical evidence for glycemic outcomes in at-risk and diabetic populations. A synbiotic formula—one that pairs probiotics with prebiotic fiber—is associated with stronger and more sustained effects than standalone probiotic supplementation.[6]
Can probiotics reverse prediabetes?
"Reverse" is a strong word, and the clinical evidence doesn't support that framing in isolation. What the research does show is that probiotic supplementation—particularly multi-strain formulas paired with dietary changes—can produce meaningful reductions in fasting blood glucose, HbA1c, and HOMA-IR in prediabetic individuals, potentially slowing or halting progression toward a T2D diagnosis. These effects are most pronounced when supplementation is sustained for 8 weeks or more and is accompanied by lifestyle modifications.[6]
How long does it take for probiotics to affect blood sugar?
Clinical trials showing significant glycemic improvements have generally run for 8–12 weeks. This reflects the biology: meaningful shifts in gut microbiome composition, gut barrier integrity, and the downstream hormonal and inflammatory cascades they influence take time. Short-term probiotic use (under 4–6 weeks) is unlikely to produce the same magnitude of glycemic benefit as sustained supplementation. Consistency is the most important variable in the evidence base.
Are probiotics safe for people taking metformin or other diabetes medications?
The clinical trials producing the evidence reviewed in this article were generally conducted in populations receiving standard-of-care diabetes treatment, including metformin. Probiotics are broadly considered safe alongside first-line T2D medications. That said, any supplement decision should be discussed with your prescribing physician, particularly if you are adjusting your medication regimen or monitoring your glucose response closely. Probiotics work as an adjunctive—not a substitute—for evidence-based pharmacological management.
Do prebiotics matter alongside probiotics for blood sugar?
Yes—significantly. Synbiotic formulations (probiotic + prebiotic combinations) consistently show stronger and more durable effects than probiotics alone in metabolic health trials. The prebiotic fiber—particularly inulin and acacia fiber—feeds the beneficial bacteria in the formula, extending their colonization efficiency and SCFA production in the colon. This enhanced SCFA output translates to greater GLP-1 stimulation and improved postprandial glycemic control. MicroBiome Restore includes 9 organic prebiotics alongside its 26-strain formula for precisely this reason.
The Bottom Line on Probiotics for Type 2 Diabetes and Prediabetes
The relationship between the gut microbiome and blood sugar regulation is well-established, mechanistically coherent, and now supported by a growing body of randomized controlled trials and meta-analyses. Specific probiotic strains—particularly L. acidophilus, B. lactis, L. reuteri, L. plantarum, L. rhamnosus, and Bifidobacterium species—have demonstrated clinically meaningful reductions in fasting blood glucose, HbA1c, and insulin resistance markers in both diabetic and prediabetic populations. The evidence most consistently favors multi-strain formulations paired with prebiotic support, used consistently for at least 8 weeks.
MicroBiome Restore was formulated around this evidence: 26 strains, 9 organic prebiotics, no synthetic fillers. Explore our complete formulation guide to understand how each ingredient earns its place—and why the absence of common industry additives is as important as what the formula contains.
26 Evidence-Based Strains. 9 Organic Prebiotics. Zero Fillers.
MicroBiome Restore delivers everything the research supports for comprehensive gut and metabolic health—including every strain discussed in this article—in a filler-free pullulan capsule. Every ingredient is justified by science. Nothing is there to make manufacturing easier.
References
- Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., ... & Burcelin, R. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 56(7), 1761–1772. https://doi.org/10.2337/db06-1491
- Ruan, Y., Sun, J., He, J., Chen, F., Chen, R., & Chen, H. (2015). Effect of probiotics on glycemic control: A systematic review and meta-analysis of randomized, controlled trials. PLOS ONE, 10(7), e0132121. https://doi.org/10.1371/journal.pone.0132121
- Ejtahed, H. S., Mohtadi-Nia, J., Homayouni-Rad, A., Niafar, M., Asghari-Jafarabadi, M., & Mofid, V. (2012). Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition, 28(5), 539–543. https://doi.org/10.1016/j.nut.2011.08.013
- Mobini, R., Tremaroli, V., Ståhlman, M., Karlsson, F., Levin, M., Ljungberg, M., ... & Bäckhed, F. (2017). Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: A randomized controlled trial. Diabetes, Obesity and Metabolism, 19(4), 579–589. https://doi.org/10.1111/dom.12861
- Tonucci, L. B., Olbrich dos Santos, K. M., Licursi de Oliveira, L., Rocha Ribeiro, S. M., & Duarte Martino, H. S. (2017). Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clinical Nutrition, 36(1), 85–92. https://doi.org/10.1016/j.clnu.2015.11.011
- Li, C., Li, X., Han, H., Cui, H., Peng, M., Wang, G., & Wang, Z. (2016). Effect of probiotics on metabolic profiles in type 2 diabetes mellitus: A meta-analysis of randomized, controlled trials. Medicine (Baltimore), 95(26), e4088. https://doi.org/10.1097/MD.0000000000004088
- Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., ... & Wang, J. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 490(7418), 55–60. https://doi.org/10.1038/nature11450
- Asemi, Z., Zare, Z., Shakeri, H., Sabihi, S. S., & Esmaillzadeh, A. (2013). Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Annals of Nutrition & Metabolism, 63(1–2), 1–9. https://doi.org/10.1159/000349922
- Firouzi, S., Majid, H. A., Ismail, A., Kamaruddin, N. A., & Barakatun-Nisak, M. Y. (2017). Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial. European Journal of Nutrition, 56(4), 1535–1550. https://doi.org/10.1007/s00394-016-1199-8
- Kasińska, M. A., & Drzewoski, J. (2015). Effectiveness of probiotics in type 2 diabetes: A meta-analysis. Polish Archives of Internal Medicine, 125(11), 803–813. https://doi.org/10.20452/pamw.3156
'%3e%3cg%20id='Final-Copy-2_2_'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st0'%20d='M7.4,12.8h6.8l3.1-11.6H7.4C4.2,1.2,1.6,3.8,1.6,7S4.2,12.8,7.4,12.8z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3cg%20id='final---dec.11-2020'%3e%3cg%20id='_x30_208-our-toggle'%20transform='translate(-1275.000000,%20-200.000000)'%3e%3cg%20id='Final-Copy-2'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st1'%20d='M22.6,0H7.4c-3.9,0-7,3.1-7,7s3.1,7,7,7h15.2c3.9,0,7-3.1,7-7S26.4,0,22.6,0z%20M1.6,7c0-3.2,2.6-5.8,5.8-5.8%20h9.9l-3.1,11.6H7.4C4.2,12.8,1.6,10.2,1.6,7z'/%3e%3cpath%20id='x'%20class='st2'%20d='M24.6,4c0.2,0.2,0.2,0.6,0,0.8l0,0L22.5,7l2.2,2.2c0.2,0.2,0.2,0.6,0,0.8c-0.2,0.2-0.6,0.2-0.8,0%20l0,0l-2.2-2.2L19.5,10c-0.2,0.2-0.6,0.2-0.8,0c-0.2-0.2-0.2-0.6,0-0.8l0,0L20.8,7l-2.2-2.2c-0.2-0.2-0.2-0.6,0-0.8%20c0.2-0.2,0.6-0.2,0.8,0l0,0l2.2,2.2L23.8,4C24,3.8,24.4,3.8,24.6,4z'/%3e%3cpath%20id='y'%20class='st3'%20d='M12.7,4.1c0.2,0.2,0.3,0.6,0.1,0.8l0,0L8.6,9.8C8.5,9.9,8.4,10,8.3,10c-0.2,0.1-0.5,0.1-0.7-0.1l0,0%20L5.4,7.7c-0.2-0.2-0.2-0.6,0-0.8c0.2-0.2,0.6-0.2,0.8,0l0,0L8,8.6l3.8-4.5C12,3.9,12.4,3.9,12.7,4.1z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Your Privacy Choices
Share and get 15% off!
Simply share this product on one of the following social networks and you will unlock 15% off!